Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021)

Harmony Biosciences Holdings (HRMY) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $192000.0 as the latest value for Q1 2021.

  • Quarterly Non-Current Deffered Revenue changed N/A to $192000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $192000.0 through Mar 2021, changed N/A year-over-year, with the annual reading at $212000.0 for FY2020, 26.13% down from the prior year.
  • Non-Current Deffered Revenue hit $192000.0 in Q1 2021 for Harmony Biosciences Holdings, down from $212000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $305000.0 in Q3 2020 to a low of $192000.0 in Q1 2021.
  • Historically, Non-Current Deffered Revenue has averaged $249000.0 across 3 years, with a median of $249500.0 in 2019.
  • Biggest YoY gain for Non-Current Deffered Revenue was 26.13% in 2020; the steepest drop was 26.13% in 2020.
  • Year by year, Non-Current Deffered Revenue stood at $287000.0 in 2019, then fell by 26.13% to $212000.0 in 2020, then fell by 9.43% to $192000.0 in 2021.
  • Business Quant data shows Non-Current Deffered Revenue for HRMY at $192000.0 in Q1 2021, $212000.0 in Q4 2020, and $305000.0 in Q3 2020.